AstraZeneca will pay insitro $40 million up front, with up to about $1.46 billion in milestones to follow, for liver and heart targets. At 2.7% of the disclosed total, the upfront leaves most of the value tied to targets insitro has yet to deliver.
Perspective Coverage
3 publishers
- Builder
- Builder 32%
- Operator
- Operator 31%
- Investor
- Investor 37%
Reality
- Evidence55
- Adoption40
- Hype gap+30
- Incentives60
- Confidence70
Lotte Biologics will make drug substance for several Alvotech antibody biosimilars at its 40,000-liter plant in Syracuse, New York. Alvotech's CEO said its network now covers a decade of pipeline demand, so more work for Lotte depends on how many Alvotech products launch.
Reality
- Evidence45
- Adoption25
- Hype gap+20
- Incentives70
- Confidence60
The company's head of life sciences told Reuters that real lab work is still the final test in biology. Anthropic has not said which experiments the lab is running, and it has yet to run a clinical trial.
Perspective Coverage
5 publishers
- Builder
- Builder 28%
- Operator
- Operator 35%
- Investor
- Investor 37%
Reality
- Evidence55
- Adoption40
- Hype gap+30
- Incentives70
- Confidence57
Orum halted an earlier antibody-degrader conjugate in April last year after a death and unexplained liver toxicity. The candidate Bristol Myers is testing in leukemia sits on the same platform, and a second in-house candidate uses the same degrader.
Reality
- Evidence32
- Adoption40
- Hype gap+35
- Incentives70
- Confidence45
MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.
Reality
- Evidence61
- Adoption58
- Hype gap+12
- Incentives74
- Confidence63